Sonal.pingle at 04:40, 7 October 2011

2011-10-07T04:40:06Z

New page

To go back to the main page, click [http://dolcera.com/wiki/index.php?title=Cancer_Vaccines_-_Clinical_Trial_Analysis#Melanoma_Cancer here]
 
 

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|bgcolor = "#4F81BD"|'''S.No.'''
|bgcolor = "#4F81BD"|'''Drug Name'''
|bgcolor = "#4F81BD"|'''Biological Name'''
|bgcolor = "#4F81BD"|'''Developer'''
|bgcolor = "#4F81BD"|'''Current Development Phase'''
|bgcolor = "#4F81BD"|'''Additional Information'''
|bgcolor = "#4F81BD"|'''Start Date'''
|bgcolor = "#4F81BD"|'''Completion Date'''
|bgcolor = "#4F81BD"|'''Source'''
|-
|align = "center" bgcolor = "#DBE5F1"|11
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|IMF-001
|bgcolor = "#DBE5F1"|ImmunoFrontier, Inc.
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers.
|bgcolor = "#DBE5F1"|2010
|bgcolor = "#DBE5F1"|2011
|bgcolor = "#DBE5F1"|[http://clinicaltrials.gov/ct2/show?term=cancer+vaccine&rank=80 Source]
|-
|align = "center"|12
|align = "center"|<nowiki>-</nowiki>
|Lipovaxin-MM
|Lipotek Pty Ltd
|align = "center"|I
|The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body<nowiki>’</nowiki>s ability to destroy cancer cells in patients with metastatic melanoma.
|2009
|2011
|[http://clinicaltrials.gov/ct2/show?term=cancer+vaccine&rank=45 Source]
|-
|align = "center" bgcolor = "#DBE5F1"|13
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|PSMA/PRAME
|bgcolor = "#DBE5F1"|MannKind Corporation
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
|bgcolor = "#DBE5F1"|2007
|bgcolor = "#DBE5F1"|2009
|bgcolor = "#DBE5F1"|[http://clinicaltrials.gov/ct2/show/NCT00423254?term=MKC1106-PP&rank=1 Source]
|-
|align = "center"|14
|align = "center"|<nowiki>-</nowiki>
|MKC1106-MT, MKCC1106-MT
|Mannkind Corporation
|align = "center"|I
|A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
|2008
|2010
|[http://clinicaltrials.gov/ct2/show?term=cancer+vaccine&rank=44 Source]
|-
|align = "center" bgcolor = "#DBE5F1"|15
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"| MKC1106-MT
|bgcolor = "#DBE5F1"|Mannkind Corporation
|align = "center" bgcolor = "#DBE5F1"|II
|bgcolor = "#DBE5F1"|The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
|bgcolor = "#DBE5F1"|2010
|bgcolor = "#DBE5F1"|2012
|bgcolor = "#DBE5F1"|[http://clinicaltrials.gov/ct2/show?term=cancer+vaccine&rank=49 Source]
|-
|align = "center"|16
|align = "center"|<nowiki>-</nowiki>
|V934/V935
|Merck
|align = "center"|I
|Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
|2008
|2011
|[http://clinicaltrials.gov/ct2/show/NCT00753415?term=V934%2FV935&rank=1 Source]
|-
|align = "center" bgcolor = "#DBE5F1"|17
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|Pegylated Interferon-Alpha 2b
|bgcolor = "#DBE5F1"|NewLink Genetics
|align = "center" bgcolor = "#DBE5F1"|II
|bgcolor = "#DBE5F1"|The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily).
|bgcolor = "#DBE5F1"|2008
|bgcolor = "#DBE5F1"|2011
|bgcolor = "#DBE5F1"|[http://clinicaltrials.gov/ct2/show/NCT00746746?term=HyperAcute-Melanoma&rank=1 Source]
|-
|align = "center"|18
|align = "center"|<nowiki>-</nowiki>
|align = "center"|<nowiki>-</nowiki>
|Sanofi-Aventis
|align = "center"|II
|Terminated Objective was: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
|2008
|2010
|[http://clinicaltrials.gov/ct2/show/NCT00613509?term=ALVAC+sanofi&rank=1 Source]
|-
|align = "center" bgcolor = "#DBE5F1"|19
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|AdhTAP
|bgcolor = "#DBE5F1"|TapImmune
|align = "center" bgcolor = "#DBE5F1"|Preclinical
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|-
|align = "center"|20
|align = "center"|<nowiki>-</nowiki>
| Dacarbazine (DTIC), Temozolomide (TMZ)
|Vical/AnGes
|III
|Approval possibly by 2013
|2006
|2012
|[http://clinicaltrials.gov/ct2/show/NCT00395070?term=Allovectin-7&rank=1 Source]
|-
|}

 
 
To go back to the main page, click [http://dolcera.com/wiki/index.php?title=Cancer_Vaccines_-_Clinical_Trial_Analysis#Melanoma_Cancer here]

Melanoma Trials - Revision history

Sonal.pingle at 04:40, 7 October 2011